Research Progress of Neutrophil Gelatinase-associated Lipocalin in Coronary Heart Disease

doi:10.12114/j.issn.1007-9572.2020.00.096

Abstract

Abstract: In recent years，the rapid development of cardiac markers has improved the overall level of cardiovascular disease's diagnosis.Research findings have shown that neutrophil gelatinase-associated lipocalin（NGAL），as a marker of acute renal injury（AKI），is closely related to the severity of coronary heart disease，adverse prognosis and the occurrence of future cardiovascular events.NGAL is also a potential marker in coronary heart disease.The purpose of this review is to elucidate the origin and nature of NGAL and the relationship between NGAL and the severity of coronary artery disease，stable coronary heart disease，acute coronary syndrome（ACS）and future coronary heart disease events.And it aims to provide a promising reference direction for the researches of biomarkers in coronary heart disease.

Key words: Coronary disease, Neutrophil gelatinase-associated lipocalin, Biomarkers, Coronary artery disease, Stable coronary heart disease, Acute coronary syndrome, Future coronary heart disease events

摘要： 近年来心脏标志物领域有了飞速的发展，推动了整体心血管疾病诊断水平的提高。研究表明，中性粒细胞明胶酶相关脂质运载蛋白（NGAL）作为急性肾损伤（AKI）的一种标志物，与冠心病患者疾病的严重程度、不良预后及未来心血管事件的发生相关，是冠心病领域的潜力标志物。本文就NGAL的来源与性质及NGAL与冠状动脉病变严重程度、稳定型冠心病、急性冠脉综合征（ACS）、未来冠心病事件的关系的研究进展做一综述，希望能够为冠心病生物标志物领域的研究提供新的参考方向。

关键词: 冠心病, 中性粒细胞明胶酶相关脂质运载蛋白, 生物标志物, 冠状动脉病变, 稳定型冠心病, 急性冠脉综合征, 未来冠心病事件

CUI Xiaohao,YANG Zhiming. Research Progress of Neutrophil Gelatinase-associated Lipocalin in Coronary Heart Disease　[J]. Chinese General Practice, 2020, 23(27): 3492-3495. DOI: 10.12114/j.issn.1007-9572.2020.00.096.
崔小豪,杨志明. 中性粒细胞明胶酶相关脂质运载蛋白在冠心病中的研究进展[J]. 中国全科医学, 2020, 23(27): 3492-3495. DOI: 10.12114/j.issn.1007-9572.2020.00.096.

References

［1］PIEPOLI M F，CORRà U，DENDALE P，et al．Challenges in secondary prevention after acute myocardial infarction：a call for action［J］．Eur J Cardiovasc Nurs，2017，16（5）：369-380．DOI：10.1177/1474515117702594.
［2］KHAWAJA S，JAFRI L，SIDDIQUI I，et al．The utility of neutrophil gelatinase-associated Lipocalin（NGAL）as a marker of acute kidney injury（AKI）in critically ill patients［J］．Biomark Res，2019，7：4．DOI：10.1186/s40364-019-0155-1.
［3］KJELDSEN L，JOHNSEN A H，SENGEL?V H，et al．Isolation and primary structure of NGAL，a novel protein associated with human neutrophil gelatinase［J］．J Biol Chem，1993，268（14）：10425-10432.
［4］PEDERSEN K R，RAVN H B，HJORTDAL V E，et al．Neutrophil gelatinase-associated lipocalin（NGAL）：validation of commercially available ELISA［J］．Scand J Clin Lab Invest，2010，70（5）：374-382．DOI：10.3109/00365513.2010.486868.
［5］HELANOVA K，SPINAR J，PARENICA J.Diagnostic and prognostic utility of neutrophil gelatinase-associated lipocalin（NGAL）in patients with cardiovascular diseases——review［J］．Kidney Blood Press Res，2014，39（6）：623-629．DOI：10.1159/000368474.
［6］PRECEK J，HUTYRA M，KOVáCIK F，et al．Biomarkers of renal function in prognostic stratification of patients with acute coronary syndrome［J］．Cor Vasa，2018，60（2）：e148-154．DOI：10.1016/j.crvasa.2017.05.018.
［7］HEMDAHL A L，GABRIELSEN A，ZHU C Y，et al．Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction［J］．Arterioscler Thromb Vasc Biol，2006，26（1）：136-142．DOI：10.1161/01.ATV.0000193567.88685.f4.
［8］EILENBERG W，STOJKOVIC S，PIECHOTA-POLANCZYK A，et al．Neutrophil gelatinase-associated lipocalin（NGAL）is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro［J］．Eur J Vasc Endovasc Surg，2016，51（5）：623-631．DOI：10.1016/j.ejvs.2016.01.009.
［9］SUNG H K，CHAN Y K，HAN M，et al．Lipocalin-2（NGAL）attenuates autophagy to exacerbate cardiac apoptosis induced by myocardial ischemia［J］．J Cell Physiol，2017，232（8）：2125-2134．DOI：10.1002/jcp.25672.
［10］ZOGRAFOS T，HALIASSOS A，KOROVESIS S，et al．Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease［J］．Am J Cardiol，2009，104（7）：917-920．DOI：10.1016/j.amjcard.2009.05.023.
［11］SOYLU K，AKSAN G，NAR G，et al．Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome［J］．Anatol J Cardiol，2015，15（6）：450-455．DOI：10.5152/akd.2014.5513.
［12］KATAGIRI M，TAKAHASHI M，DOI K，et al．Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease［J］．Heart Vessels，2016，31（10）：1595-1602．DOI：10.1007/s00380-015-0776-8.
［13］李超，彭瑜，高涵翔，等．血浆中性粒细胞明胶酶相关脂质运载蛋白水平与急性ST段抬高型心肌梗死病变严重程度的关系［J］．中国循环杂志，2018，33（3）：222-226．DOI：10.3969/j.issn.1000-3614.2018.03.004.
LI C，PENG Y，GAO H X，et al．Relationship between plasma level of neutrophil gelatinase-associated lipocalin and coronary lesion severity in patients with acute ST-elevation myocardial infarction［J］．Chinese Circulation Journal，2018，33（3）：222-226．DOI：10.3969/j.issn.1000-3614.2018.03.004.
［14］MALYSZKO J，BACHORZEWSKA-GAJEWSKA H，MALYSZKO J S，et al．Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease［J］．Nephrology（Carlton），2008，13（2）：153-156．DOI：10.1111/j.1440-1797.2007.00899.x.
［15］PAULSSON J，DADFAR E，HELD C，et al．Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease［J］．Atherosclerosis，2007，192（2）：328-334．DOI：10.1016/j.atherosclerosis.2006.08.003.
［16］CHAKRABARTI S，PATEL K D.Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils［J］．J Leukoc Biol，2005，78（1）：279-288．DOI：10.1189/jlb.1004612.
［17］SIVALINGAM Z，ERIK MAGNUSSON N，GROVE E L，et al．Neutrophil gelatinase-associated lipocalin（NGAL）and cardiovascular events in patients with stable coronary artery disease［J］．Scand J Clin Lab Invest，2018，78（6）：470-476．DOI：10.1080/00365513.2018.1499956.
［18］LINDBERG S，PEDERSEN S H，MOGELVANG R，et al．Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention［J］．J Am Coll Cardiol，2012，60（4）：339-345．DOI：10.1016/j.jacc.2012.04.017.
［19］ZYKOV M V，KASHTALAP V V，BYKOVA I S，et al．Clinical and prognostic value of serum neutrophil gelatinase-associated lipocalin in patients with ST-segment elevation myocardial infarction［J］．Kardiologiia，2016，56（5）：24-29．DOI：10.18565/cardio.2016.5.24-29.
［20］LIM Y M，MOON J Y，MIN D，et al．Serial measurements of neutrophil gelatinase-associated lipocalin：prognostic value in patients with ST-segment elevation myocardial infarction treated with a primary percutaneous coronary intervention［J］．Coron Artery Dis，2017，28（8）：690-696．DOI：10.1097/MCA.0000000000000542.
［21］FAN Y，ZOU C.Prognostic value of neutrophil gelatinase-associated lipocalin in patients with acute ST-segment elevation myocardial infarction：a meta-analysis［J］．Eur J Prev Cardiol，2019，26（4）：444-446．DOI：10.1177/2047487318783254.
［22］NYMO S H，HARTFORD M，UELAND T，et al．Serum neutrophil gelatinase-associated lipocalin（NGAL）concentration is independently associated with mortality in patients with acute coronary syndrome［J］．Int J Cardiol，2018，262：79-84．DOI：10.1016/j.ijcard.2018.03.028.
［23］LAHIRI A，ALEX A G，GEORGE P V.Estimating the prevalence of elevated plasma neutrophil gelatinase associated lipocalin level in patients with acute coronary syndromes and its association with outcomes［J］．Indian Heart J，2018，70（2）：220-224．DOI：10.1016/j.ihj.2017.06.005.
［24］SHALENKOVA M A，MIKHAILOVA Z D，KLIMKIN P F.NGAL as a marker for some extrarenal complications in acute coronary syndrome［J］．Kardiologiia，2018（S3）：19-26.
［25］MARTíNEZ-MARTíNEZ E，BUONAFINE M，BOUKHALFA I，et al．Aldosterone target NGAL（neutrophil gelatinase-associated lipocalin）is involved in cardiac remodeling after myocardial infarction through NFκB pathway［J］．Hypertension，2017，70（6）：1148-1156．DOI：10.1161/HYPERTENSIONAHA.117.09791.
［26］NAKA K K，PAPATHANASSIOU K，BECHLIOULIS A，et al．Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2 diabetes mellitus［J］．Clin Biochem，2018，53：31-37．DOI：10.1016/j.clinbiochem.2017.12.010.
［27］CHONG J J H，PRINCE R L，THOMPSON P L，et al．Association between plasma neutrophil gelatinase-associated lipocalin and cardiac disease hospitalizations and deaths in older women［J］．J Am Heart Assoc，2019，8（1）：e011028．DOI：10.1161/JAHA.118.011028.
［28］FASSETT R G，ROBERTSON I K，BALL M J，et al．Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease：a post hoc analysis of the LORD trial［J］．Nephrol Dial Transplant，2012，27（1）：182-189．DOI：10.1093/ndt/gfr193.
［29］LáBR K，?PINAR J，PARENICA J，et al．Renal functions and prognosis stratification in chronic heart failure patients and the importance of neutrophil gelatinase-associated lipocalin［J］．Kidney Blood Press Res，2018，43（6）：1865-1877．DOI：10.1159/000495819.
［30］CHEN S，CHEN X C，LOU X H，et al．Determination of serum neutrophil gelatinase-associated lipocalin as a prognostic biomarker of acute spontaneous intracerebral hemorrhage［J］．Clin Chim Acta，2019，492：72-77．DOI：10.1016/j.cca.2019.02.009.
［31］MOSCHEN A R，ADOLPH T E，GERNER R R，et al．Lipocalin-2：a master mediator of intestinal and metabolic inflammation［J］．Trends Endocrinol Metab，2017，28（5）：388-397．DOI：10.1016/j.tem.2017.01.003.
［61］MATSUSHITA S，YONEKURA K，MERA K，et al．Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy［J］．J Dermatol，2011，38（10）：996-998．DOI:10.1111/j.1346-8138.2010.01149.x.
［62］BELEZNAY K M，LEVESQUE M A，GILL S.Response to 5-fluorouracil in metastatic extramammary Paget disease of the scrotum presenting as pancytopenia and back pain［J］．Curr Oncol，2009，16（5）：81-83．DOI:10.3747/co.v16i5.374.
［63］TAKAHAGI S，NODA H，KAMEGASHIRA A，et al．Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy［J］．J Dermatol，2009，36（8）：457-461．DOI:10.1111/j.1346-8138.2009.00676.x.
［64］MOCHITOMI Y，SAKAMOTO R，GUSHI A，et al．Extramammary Paget's disease/carcinoma successfully treated with a combination chemotherapy：report of two cases［J］．J Dermatol，2005，32（8）：632-637．DOI:10.1111/j.1346-8138.2005.tb00812.x.
［65］WATANABE Y，HOSHIAI H，UEDA H，et al．Low-dose mitomycin C，etoposide，and cisplatin for invasive vulvar Paget's disease［J］．Int J Gynecol Cancer，2002，12（3）：304-307．DOI:10.1046/j.1525-1438.2002.01126.x.
［66］AL HALLAK M N，ZOUAIN N.Extramammary perianal Paget's disease［J］．Case Rep Gastroenterol，2009，3（3）：332-337．DOI:10.1159/000256382.
［67］ZOLLO J D，ZEITOUNI N C.The Roswell park cancer institute experience with extramammary Paget's disease［J］．Br J Dermatol，2000，142（1）：59-65．DOI:10.1046/j.1365-2133.2000.03242.x.
［68］YE J N，RHEW D C，YIP F，et al．Extramammary Paget's disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid：a case report［J］．Cutis，2006，77（4）：245-250.
［69］ITO T，KAKU Y，NAGAE K，et al．Tumor thickness as a prognostic factor in extramammary Paget's disease［J］．J Dermatol，2015，42（3）：269-275．DOI:10.1111/1346-8138.12764.
［70］KARAM A，DORIGO O.Treatment outcomes in a large cohort of patients with invasive extramammary Paget's disease［J］．Gynecol Oncol，2012，125（2）：346-351．DOI:10.1016/j.ygyno.2012.01.032.
［71］HERREL L A 1，WEISS A D，GOODMAN M，et al．Extramammary Paget's disease in males:survival outcomes in 495 patients［J］.Ann Surg Oncol，2015，22（5）:1625-1630．DOI：10.1245/s10434-014-4139-y.
［72］WANG Z，LU M，DONG G Q，et al．Penile and scrotal Paget's disease:130 Chinese patients with long-term follow-up［J］.BJU Int，2008，102（4）：485-488．DOI:10.1111/j.1464-410X.2008.07575.x.

[1]	ZHOU Qibao, LUO Xiao, CHEN Ling, CAO Junda, LI Juxiang, XU Jinsong, SU Hai. Clinical Study on the Diagnostic Value of Circadian Variability of Systolic Blood Pressure Combined with SDNN in Coronary Heart Disease [J]. Chinese General Practice, 2025, 28(30): 3760-3765.
[2]	WU Wenjun, WEI Jingjing, LI Xue, REN Hongjie, YU Rui, PENG Guangcao, ZHU Mingjun. Regularity of Prescriptions for Coronary Heart Disease with Hypertension Based on Latent Structure and Association Rules [J]. Chinese General Practice, 2025, 28(30): 3787-3795.
[3]	LI Ling, LI Yaping, QIAN Shixing, NIE Jing, LU Chunhua, LI Xia. Research on Influencing Factors and Risk Prediction of Cognitive Function in Community-dwelling Middle-aged and Elderly People [J]. Chinese General Practice, 2025, 28(30): 3773-3778.
[4]	LI Jiaxin, LIU Zhonghui, XIE Shuo, FU Zhifang, SUN Dan, JIAO Hongmei. Trajectory in Biomarkers of Metabolic and Inflammatory States as Early Predictors of Chronic Critical Illness in Aging Patients [J]. Chinese General Practice, 2025, 28(24): 2993-2999.
[5]	YANG Ji, ZHANG Yao, ZHAO Yingqiang, ZHANG Qiuyue. Evaluation of the Effectiveness of TCM Three-level Prevention and Control Model in the Management of Patients with Coronary Heart Disease and Stroke: a Single-center, Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(22): 2750-2761.
[6]	CHEN Fei, WANG Jinying, YU Haibo, LI Xin, ZHANG Jiajia, SHEN Man, ZHAN Xiaokai, TANG Ran, FAN Sibin, ZHAO Fengyi, ZHANG Tianyu, HUANG Zhongxia. Significance of Elevated Urinary NGAL, TIM-1, VCAM-1 and Activin A in Patients with New Diagnosed Multiple Myeloma [J]. Chinese General Practice, 2025, 28(22): 2740-2749.
[7]	CHAI Yiyi, YE Qingfang, LIN Ping, LI Ling. Current Status and Influencing Factors of Motoric Cognitive Risk in Patients with Coronary Artery Disease in Frigid Zone [J]. Chinese General Practice, 2025, 28(14): 1730-1736.
[8]	HUANG Chuanying, LIAO Xiaoyang, YANG Rong, LI Dongze, ZHANG Peng, JIA Yu, LIU Lidi. Interpretation of the Clinical Statement for Management of Female Cardiac Emergencies in 2024 [J]. Chinese General Practice, 2025, 28(12): 1427-1432.
[9]	JIA Shuo, CHENG Gong, GUAN Lei, FENG Panpan, XU Bailing, FANG Wei, ZHANG Ji. Diagnostic Performance of SPECT in Patients with Coronary Microcirculation Disturbance after PCI [J]. Chinese General Practice, 2025, 28(09): 1122-1127.
[10]	MA Xiaoxuan, WANG Rongqi. Research Progress in Metabolomics for HCC Diagnosis and Treatment [J]. Chinese General Practice, 2025, 28(08): 1017-1022.
[11]	WANG Rui, OUYANG Lina, WU Qian, NIU Yuanyuan, LI Guilan, ZHU Li. The Value of CT-FFR in Predicting Major Adverse Cardiovascular Events in Patients with Obstructive Coronary Artery Disease [J]. Chinese General Practice, 2025, 28(06): 713-719.
[12]	YUE Haitao, HE Chanchan, CHENG Yuyou, ZHANG Sencheng, WU You, MA Jing. Coronary Heart Disease Risk Prediction Model Based on Machine Learning [J]. Chinese General Practice, 2025, 28(04): 499-509.
[13]	ZHANG Ming, WANG Wenjuan, HAO Wen, CHEN Jibin, XIA Wei, SHAO Yibing, WANG Bin. Clinical Research of Obstructive Sleep Apnea and Acute Coronary Syndrome: Current Status and Future Direction [J]. Chinese General Practice, 2025, 28(03): 257-261.
[14]	YANG Hong, LIU Cheng, LIU Sen, SHAO Qiqi, YAO Yuanhao, FU Zhenyan. Association of Residual Cholesterol with Vulnerable Plaques in Non-culprit Lesions Progressing to Major Adverse Cardiovascular Events [J]. Chinese General Practice, 2025, 28(03): 299-304.
[15]	SUN Xuechun, DU Zhiyong, YU Huahui, LYU Qianwen, JIAO Xiaolu, WANG Yu, QIN Yanwen. Value of Lysophospholipid Metabolites in Prognosis of Major Adverse Cardiac Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: a Prospective Cohort Study [J]. Chinese General Practice, 2024, 27(36): 4540-4545.